IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation
Hemasphere. 2024 Mar 10;8(3):e44.
doi: 10.1002/hem3.44.
eCollection 2024 Mar.
1 Hematology Department, Hôpital Jean Minjoz CHU Besançon Besançon France.
2 Hematology Department, Hôpital Haut-Lévêque CHU Bordeaux Bordeaux France.
3 Hematology Department Hôpital Saint-Louis Paris France.
4 Hematology Department, Hôpital Brabois CHU Nancy Nancy France.
5 Hematology Department CHU Brest Brest France.
6 Hematology Department, CHU de Lille University of Lille Lille France.
7 Hematology Department CHU Poitiers Poitiers France.
8 Hematology Department Institut Paoli-Calmettes Marseille France.
9 Hematology Department IUCT Oncopole Toulouse France.
10 Hematology Department Institut Gustave Roussy Villejuif France.
11 Hematology Department, ICANS CHU Strasbourg Strasbourg France.
12 Hematology Department CHU Caen Caen France.
13 Methodological and Quality of Life in Oncology Unit, University Hospital of Besançon, Franche-Comté University, INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, UMR 1098 Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique Besançon France.
14 Pharmacy Department, INSERM, Etablissement Français du Sang, Bourgogne Franche Comté, UMR 1098 Interactions Hôte-Greffon-Tumeur/Inginérie Cellulaire et Génique Besançon France.
15 Hematology Department Centre Hospitalier Universitaire de Besancon Besançon France.